MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 318758 | Name: Streptomycin sulfate
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Streptomycin is an antibiotic (antimycobacterial) drug, the first of a class of drugs called aminoglycosides to be discovered, and it was the first effective treatment for tuberculosis. It is derived from the actinobacterium Streptomyces griseus. Streptomycin is a bactericidal antibiotic. Adverse effects of this medicine are ototoxicity, nephrotoxicity, fetal auditory toxicity, and neuromuscular paralysis.

Chemical Structure

Streptomycin sulfate
Streptomycin sulfate
CAS#3810-74-0 (sulfate)

Theoretical Analysis

MedKoo Cat#: 318758

Name: Streptomycin sulfate

CAS#: 3810-74-0 (sulfate)

Chemical Formula: C21H38N7O12

Exact Mass: 0.0000

Molecular Weight: 580.57

Elemental Analysis: C, 43.45; H, 6.60; N, 16.89; O, 33.07

Price and Availability

Size Price Availability Quantity
1g USD 250.00 2 Weeks
5g USD 450.00 2 Weeks
10g USD 750.00 2 Weeks
25g USD 1,350.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
3810-74-0 (sulfate) 3810-74-0 (free base)
Synonym
NSC 14083; NSC14083; NSC-14083; Streptomycin; Strepcen; Streptomicina; Streptomycin sulfate.
IUPAC/Chemical Name
bis(1,1'-((1R,2R,3S,4R,5R,6S)-4-(((2R,3R,4R,5S)-3-(((2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)tetrahydro-2H-pyran-2-yl)oxy)-4-formyl-4-hydroxy-5-methyltetrahydrofuran-2-yl)oxy)-2,5,6-trihydroxycyclohexane-1,3-diyl)diguanidine) tris(sulfate)
InChi Key
QTENRWWVYAAPBI-YCRXJPFRSA-N
InChi Code
InChI=1S/2C21H39N7O12.3H2O4S/c2*1-5-21(36,4-30)16(40-17-9(26-2)13(34)10(31)6(3-29)38-17)18(37-5)39-15-8(28-20(24)25)11(32)7(27-19(22)23)12(33)14(15)35;3*1-5(2,3)4/h2*4-18,26,29,31-36H,3H2,1-2H3,(H4,22,23,27)(H4,24,25,28);3*(H2,1,2,3,4)/t2*5-,6-,7+,8-,9-,10-,11+,12-,13-,14+,15+,16-,17-,18-,21+;;;/m00.../s1
SMILES Code
OS(=O)(O)=O.OC[C@H]1[C@H](O)[C@@H](O)[C@H](NC)[C@H](O[C@@H]2[C@](C=O)(O)[C@H](C)O[C@H]2O[C@H]3[C@@H]([C@H]([C@H](NC(N)=N)[C@@H](O)[C@@H]3NC(N)=N)O)O)O1.OC[C@H]4[C@H](O)[C@@H](O)[C@H](NC)[C@H](O[C@@H]5[C@](C=O)(O)[C@H](C)O[C@H]5O[C@H]6[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]6NC(N)=N)O4.O=S(O)(O)=O.O=S(O)(O)=O
Appearance
Solid powder
Purity
>95% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Other CAS# 15105-93-8, 298-39-5, 67479-32-7, 8018-05-1, 82115-93-3, 85027-84-5.
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Streptolydigin inhibits nucleic acid chain elongation by binding to RNA polymerase, thus inhibiting RNA synthesis inside a cell. Streptolydigin inhibits bacterial RNA polymerase, but not eukaryotic RNA polymerase.
In vitro activity:
This study examined the effect of streptomycin on melanogenesis and antioxidant defense system in cultured normal human melanocytes (HEMa-LP). Streptomycin induced concentration-dependent loss in melanocytes viability. EC50 value was about 5.0 mM. It has been shown that streptomycin causes inhibition of tyrosinase activity and reduces melanin content in human melanocytes in a concentration-dependent manner. Reference: Mol Cell Biochem. 2013 Nov;383(1-2):77-84. https://pubmed.ncbi.nlm.nih.gov/23867989/
In vivo activity:
A streptomycin pre-treatment mouse model could be used to improve enteric infection with MAP and investigate other modifications underlying MAP enteritis. Streptomycin pre-treatment of mice followed by Mycobacterium avium subsp. paratuberculosis (MAP) gavage consistently improved bacterial infection post-oral inoculation. This model led to chronic MAP infection of the intestines and mesenteric lymph nodes (MLNs) up to 24-weeks post-gavage, however there was no evidence of inflammation or disease. Reference: Gut Pathog. 2023 Oct 3;15(1):46. https://pubmed.ncbi.nlm.nih.gov/37789445/

Preparing Stock Solutions

The following data is based on the product molecular weight 580.57 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Song Y, Fan Z, Bai X, Liu W, Han Y, Xu L, Wang M, Li J, Zheng Q, Zhang D, Wang H. PARP-1-modulated AIF translocation is involved in streptomycin-induced cochlear hair cell death. Acta Otolaryngol. 2016 Jun;136(6):545-50. doi: 10.3109/00016489.2016.1143968. Epub 2016 Mar 10. PMID: 26963167; PMCID: PMC4861077. 2. Wrześniok D, Beberok A, Otręba M, Buszman E. Effect of streptomycin on melanogenesis and antioxidant status in melanocytes. Mol Cell Biochem. 2013 Nov;383(1-2):77-84. doi: 10.1007/s11010-013-1756-x. Epub 2013 Jul 19. PMID: 23867989. 3. Duffy SC, Lupien A, Elhaji Y, Farag M, Marcus V, Behr MA. Establishment of persistent enteric mycobacterial infection following streptomycin pre-treatment. Gut Pathog. 2023 Oct 3;15(1):46. doi: 10.1186/s13099-023-00573-w. PMID: 37789445; PMCID: PMC10546655. 4. Sancho E, Granados-Chinchilla F, Barquero-Calvo E. Determination of streptomycin and doxycycline using LC/MS towards an effective treatment against an experimental Brucella abortus infection in mice. J Microbiol Methods. 2022 Mar;194:106436. doi: 10.1016/j.mimet.2022.106436. Epub 2022 Feb 25. PMID: 35219705.
In vitro protocol:
1. Song Y, Fan Z, Bai X, Liu W, Han Y, Xu L, Wang M, Li J, Zheng Q, Zhang D, Wang H. PARP-1-modulated AIF translocation is involved in streptomycin-induced cochlear hair cell death. Acta Otolaryngol. 2016 Jun;136(6):545-50. doi: 10.3109/00016489.2016.1143968. Epub 2016 Mar 10. PMID: 26963167; PMCID: PMC4861077. 2. Wrześniok D, Beberok A, Otręba M, Buszman E. Effect of streptomycin on melanogenesis and antioxidant status in melanocytes. Mol Cell Biochem. 2013 Nov;383(1-2):77-84. doi: 10.1007/s11010-013-1756-x. Epub 2013 Jul 19. PMID: 23867989.
In vivo protocol:
1. Duffy SC, Lupien A, Elhaji Y, Farag M, Marcus V, Behr MA. Establishment of persistent enteric mycobacterial infection following streptomycin pre-treatment. Gut Pathog. 2023 Oct 3;15(1):46. doi: 10.1186/s13099-023-00573-w. PMID: 37789445; PMCID: PMC10546655. 2. Sancho E, Granados-Chinchilla F, Barquero-Calvo E. Determination of streptomycin and doxycycline using LC/MS towards an effective treatment against an experimental Brucella abortus infection in mice. J Microbiol Methods. 2022 Mar;194:106436. doi: 10.1016/j.mimet.2022.106436. Epub 2022 Feb 25. PMID: 35219705.
1: Coban AY, Deveci A, Sunter AT, Palomino JC, Martin A. Resazurin microtiter assay for isoniazid, rifampicin, ethambutol and streptomycin resistance detection in Mycobacterium tuberculosis: Updated meta-analysis. Int J Mycobacteriol. 2014 Dec;3(4):230-41. doi: 10.1016/j.ijmyco.2014.09.002. Epub 2014 Sep 29. Review. PubMed PMID: 26786621. 2: Baltz RH. Spontaneous and induced mutations to rifampicin, streptomycin and spectinomycin resistances in actinomycetes: mutagenic mechanisms and applications for strain improvement. J Antibiot (Tokyo). 2014 Sep;67(9):619-24. doi: 10.1038/ja.2014.105. Epub 2014 Aug 13. Review. PubMed PMID: 25118108. 3: Vouking MZ, Tamo VC, Tadenfok CN. Clinical efficacy of Rifampicin and Streptomycin in combination against Mycobacterium ulcerans infection: a systematic review. Pan Afr Med J. 2013 Aug 29;15:155. doi: 10.11604/pamj.2013.15.155.2341. Review. PubMed PMID: 24396561; PubMed Central PMCID: PMC3880821. 4: Coban AY, Deveci A, Sunter AT, Martin A. Nitrate reductase assay for rapid detection of isoniazid, rifampin, ethambutol, and streptomycin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. J Clin Microbiol. 2014 Jan;52(1):15-9. doi: 10.1128/JCM.01990-13. Epub 2013 Oct 16. Review. PubMed PMID: 24131684; PubMed Central PMCID: PMC3911439. 5: Kaiser P, Diard M, Stecher B, Hardt WD. The streptomycin mouse model for Salmonella diarrhea: functional analysis of the microbiota, the pathogen's virulence factors, and the host's mucosal immune response. Immunol Rev. 2012 Jan;245(1):56-83. doi: 10.1111/j.1600-065X.2011.01070.x. Review. PubMed PMID: 22168414. 6: Streptomycin. Tuberculosis (Edinb). 2008 Mar;88(2):162-3. doi: 10.1016/S1472-9792(08)70027-1. Review. PubMed PMID: 18486061. 7: Varelas PN, Rehman M, Pierce W, Wellwood J, Chua T, Revankar S. Vancomycin-resistant enterococcal meningitis treated with intrathecal streptomycin. Clin Neurol Neurosurg. 2008 Apr;110(4):376-80. Epub 2007 Dec 26. Review. PubMed PMID: 18162288. 8: Hilbrich L, Sleight P. Progress and problems for randomized clinical trials: from streptomycin to the era of megatrials. Eur Heart J. 2006 Sep;27(18):2158-64. Epub 2006 Jul 26. Review. PubMed PMID: 16870690. 9: Bagger-Sjoback D. Effect of streptomycin and gentamicin on the inner ear. Ann N Y Acad Sci. 1997 Dec 29;830:120-9. Review. PubMed PMID: 9616672. 10: Shea JJ Jr. The role of dexamethasone or streptomycin perfusion in the treatment of Meniere's disease. Otolaryngol Clin North Am. 1997 Dec;30(6):1051-9. Review. PubMed PMID: 9386241. 11: Graham MD. Bilateral Meniere's disease. Treatment with intramuscular titration streptomycin sulfate. Otolaryngol Clin North Am. 1997 Dec;30(6):1097-100. Review. PubMed PMID: 9386244. 12: Balyan FR, Taibah A, De Donato G, Aslan A, Falcioni M, Russo A, Sanna M. Titration streptomycin therapy in Meniere's disease: long-term results. Otolaryngol Head Neck Surg. 1998 Feb;118(2):261-6. Review. PubMed PMID: 9482564. 13: Yin T, Lu Y. [Hyaluronic acid-streptomycin perfusion of the labyrinth through the round window]. Lin Chuang Er Bi Yan Hou Ke Za Zhi. 1997 Apr;11(4):184-6. Review. Chinese. PubMed PMID: 9644169. 14: Kreiner M. Use of streptomycin-lidocaine injections in the treatment of the cluster-tic syndrome. Clinical perspectives and a case report. J Craniomaxillofac Surg. 1996 Oct;24(5):289-92. Review. PubMed PMID: 8938511. 15: Sataloff RT, McCarter A, Spiegel JR. Very high-dose streptomycin labyrinthectomy. Ear Nose Throat J. 1996 Apr;75(4):239-43. Review. PubMed PMID: 8935647. 16: Sundin GW, Bender CL. Dissemination of the strA-strB streptomycin-resistance genes among commensal and pathogenic bacteria from humans, animals, and plants. Mol Ecol. 1996 Feb;5(1):133-43. Review. PubMed PMID: 9147689. 17: Hotta K, Davies J, Yagisawa M. Aminoglycosides and aminocyclitols (other than streptomycin). Biotechnology. 1995;28:571-95. Review. PubMed PMID: 8688638. 18: Piepersberg W. Streptomycin and related aminoglycosides. Biotechnology. 1995;28:531-70. Review. PubMed PMID: 8688637. 19: Enderlin G, Morales L, Jacobs RF, Cross JT. Streptomycin and alternative agents for the treatment of tularemia: review of the literature. Clin Infect Dis. 1994 Jul;19(1):42-7. Review. PubMed PMID: 7948556. 20: Ge X, Liu J, Shea JJ. Effect on endocochlear potential of streptomycin perfusion of the cochlea in guinea pigs. Am J Otol. 1993 Mar;14(2):194-8. Review. PubMed PMID: 8503498.

View History

Nooglutyl

Nooglutyl